- SEK27.86bn
- SEK25.86bn
- SEK2.00bn
Brief: BioArctic says Rolling Sbla Initiated To U.S. FDA For Leqembi® Iqlik™ As Subcutaneous Starting Dose For Early Alzheimer's Disease Treatment Under Fast Track Status
Brief: BioArctic Says Rolling sBLA Initiated To The U.S. FDA For Leqembi As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Disease Under Fast Track Status
Brief: US FDA Approves Leqembi® IQKLIK™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
Brief: US FDA Approves Leqembi® IQKLIK ™ (lecanemab-irmb) Subcutaneous Injection For Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
Brief: Bioarctic CEO Gunilla Osswald Disposed SEK 600,851 Worth Of Co Shares On Aug 28
Brief: BioArctic Q2 Operating Profit SEK 179.1 Million
Brief: Bioarctic And Novartis Sign Option, Collaboration And License Agreement
Brief: Q2 Sales Of Leqembi Bring BioArctic SEK 162.5 Mln In Royalty
Brief: Bioarctic To Initiate Next Cohorts In Exidavnemab Phase 2A Study After Positive Safety Review
Brief: Bioarctic Receives Positive Opinion For Orphan Medicinal Product Designation In EU
Brief: BioArctic Q1 Operating Profit SEK 1,075.3 Million
Brief: Eisai Projects Leqembi® Revenue To Total JPY 76.5 Billion For FY 2025
Brief: Bioarctic Receives European Substance Patent For Exidavnemab
Europe Research Roundup: Adyen, L'Oréal, Novo Nordisk
Brief: BioArctic AB Says EU Approves Leqembi (Lecanemab) For Treatment Of Early Alzheimer's Disease
Brief: Bioarctic - EC Refers Lecanemab Marketing Authorisation Decision To Appeal Committee
Brief: Bioarctic Says Eisai Simulates Leqembi Sales To Reach JPY 250-280 Bln In FY 2027
Brief: Bioarctic Receives Orphan Drug Designation For Exidavnemab In The US
Brief: Bioarctic - Therapeutic Goods Administration Decides Not To Register Lecanemab In Australia